Authors: B. Mladosievičová Authors‘ workplace: Oddelenie klinickej patofyziológie Ústavu patologickej fyziológie LF UK, Bratis lava Published in: Čas. Lék. čes. 1999; : 138-141 Category:
As more and more oncologic patients are being cured from cancer, problems with long-term c ytostatic cardiologiccomplications have triggered and intensive investigation. Cardiotoxicity becomes a specific problem for those whosurvived cancer therapy with anthracycline. Heart failure or ventricular arrhythmias may develop from subclinicalmyocardial alterations induced by anthracycline therapy. Long-lasting monitoring of cardiac status may help toidentify those patients, whose abnormalities have progressive character and who are at risk of fatal complications
Key words: cardiotoxicity, heart failure, ventricular arrhythmias, anthracycline..
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
